- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | SAB Biotherapeutics, Inc.: SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants | 3 | GlobeNewswire (USA) | ||
| Mi | SAB BioTherapeutics slips 5%, prices $85M stock offering | 1 | Seeking Alpha | ||
| Mi | SAB Biotherapeutics prices $85M stock offering at $3.85/share | 4 | Investing.com | ||
| SAB BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | SAB Biotherapeutics, Inc.: SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| Di | SAB Biotherapeutics, Inc.: SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 11.03. | H.C. Wainwright cuts SAB Biotherapeutics price target to $7 on dilution | 1 | Investing.com | ||
| 10.03. | SAB Biotherapeutics reports early C-peptide signals in phase 1 trial | 3 | Investing.com | ||
| 10.03. | SAB Biotherapeutics, Inc.: SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes | 307 | GlobeNewswire (Europe) | Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE... ► Artikel lesen | |
| 10.03. | SAB Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.03. | SAB BioTherapeutics reports FY results | 3 | Seeking Alpha | ||
| 09.03. | SAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2025 Financial Results and Business Highlights | 195 | GlobeNewswire (Europe) | Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H... ► Artikel lesen | |
| 09.03. | SAB Biotherapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 07.01. | SAB Biotherapeutics, Inc.: SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director | 2 | GlobeNewswire (USA) | ||
| 07.01. | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.12.25 | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.25 | Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential | 5 | Investing.com | ||
| 18.12.25 | SAB Biotherapeutics, Inc.: First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D | 284 | GlobeNewswire (Europe) | Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:... ► Artikel lesen | |
| 17.12.25 | SAB Biotherapeutics, Inc.: SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D | 228 | GlobeNewswire (Europe) | Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteersStudy results support the chronic dosing... ► Artikel lesen | |
| 15.12.25 | SAB Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.11.25 | SAB BioTherapeutics reports Q3 results | 1 | Seeking Alpha |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,30 | +0,26 % | Bioxyne vs. BioNTech: Australisches MDMA-Biotech hebt Prognose nach starkem Halbjahr an | ||
| AMGEN | 298,60 | -0,85 % | Defensive Biotech-Wetten? Warum Amgen und AbbVie strukturell wachsen - kleiner Player Mesoblast im Fokus | ||
| NOVAVAX | 8,315 | -0,50 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 157,75 | -0,25 % | Biogen Inc.: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 | TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
| MAINZ BIOMED | 0,526 | -8,52 % | Quantum Cyber Aligns Strategy With Trump Administration's National Cyber Security Framework, Targets Acquisitions in Quantum and Cyber Defense Sectors | BERKELEY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber (the "Company" or "Quantum Cyber"), today announced a strategic update in response... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,835 | -0,50 % | Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics | ||
| INTELLIA THERAPEUTICS | 11,120 | -0,54 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 40,800 | 0,00 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,404 | -2,87 % | BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz | ||
| BIOMARIN PHARMACEUTICAL | 46,690 | -0,17 % | BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO | ||
| SAREPTA THERAPEUTICS | 14,710 | +1,62 % | Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,130 | -1,34 % | Canaccord reiterates Pacific Biosciences stock rating on new chemistry | ||
| EXELIXIS | 35,900 | +0,67 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,818 | +1,49 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| VAXART | 0,410 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen |
Das Unternehmen SAB BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,79 % bei einem Aktienkurs von 3,760 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SAB BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.